Percent risk of having aggressive prostate cancer for an individual patient
O P T I M I Z I N G T H E P R O S T A T E C A N C E R C A R E P A T H W AY Suspicion of malignancy based on abnormal PSA or DRE
Low-Risk 4Kscore Result of 7.5% (N = 1,510, 62%) > 7.5%
15 all men PSA ≥ 3.0
5 year = 2.4% 10 year = 5.6% 15 year = 9.9% 20 year = 16.4%
10 all men PSA ≥ 3 5 ≤ 7.5% 0 0
5 10 15 TIME FROM BASELINE (YEARS)
20
4Kscore Test Biomarkers ≤ 7.5% (N = 922, 38%) 5 year = 0% 10 year = 0.2% 15 year = 1.0% 20 year = 1.8%
The 4Kscore can aid in the reassurance of prostate biopsy decisions
NOT INDICATED FOR MEN: 1. With a previous diagnosis of prostate cancer. 2. That have received a DRE in the previous 96 hours (four days) before phlebotomy. A DRE performed after the phlebotomy is acceptable. 3. That have received within the previous six (6) months 5-alpha reductase inhibitor (5-ARI) therapy such as Avodart® (dutasteride) or Proscar® (finasteride). 4. That have undergone within the previous six (6) months any procedure or therapy to treat symptomatic BPH or any invasive, urologic procedure that may be associated with a secondary PSA elevation prior to phlebotomy.
REFERENCES 1. Parekh DJ, et al. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. Eur Uro 2015;68;464-470. 2. Par Stattin, et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case -- Control Study. Eur Urol 2015; 68 (2): 207-213. 3. Voigt JD, et al. The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate 2014;74;250-9.
